Debio 0123, a highly selective WEE1 inhibitor in adult patients with advanced solid tumors: a phase 1 dose escalation and expansion monotherapy study

Poster presented at ASCO 2025

Maria Rubinstein1, Manish R. Sharma2, Kyriakos P. Papadopoulos3, Maria-Pilar Barretina-Ginesta4, Carmen Garcia-Duran5, Mariano Ponz-Sarvise6, Andres Redondo7, Victor Moreno Garcia8, Denise Uyar9, Julian Wampfler10, Dagmar Hess11, Luis Manuel Manso Sanchez12; Jeannette Fuchs13, Emmelyne Dessein-Corne13, Noemie Luong13, Vito Dozio13, Tri Tat13, Françoise Crevel13, Victor Rodriguez-Freixinos13, Anastasios Stathis14 

1Memorial Sloan Kettering Cancer Center, NYC, NY, USA
2 START Midwest, Grand Rapids, Michigan, USA
3 START San Antonio, San Antonio, TX, USA
4 Medical Oncology Department, Institut Català d’Oncologia Girona (ICO), IDIBGI-CERCA. University of Girona (UdG), Girona, Spain
5 Gynecologic Cancer Program, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitario Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
6 Oncology Department, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
7 Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
8 START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid. Spain
9 Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, USA
10 Inselspital, Universitaetsspital Bern, Bern, Switzerland
11 Health Ostschweiz, St. Gallen, Switzerland
12 Hospital Universitario 12 de Octubre, Madrid, Spain
13 Debiopharm International SA, Lausanne, Switzerland
14 Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.